Insmed Inc. Reports 23% Revenue Growth in Q1 2025, Advances Brensocatib and TPIP Developments
Insmed Inc. reported strong Q1 2025 financial results, with $92.8 million in revenue, a 23% increase from the same period in 2024, driven by growth in its flagship product ARIKAYCE.
3 minutes to read